Galway, Ireland, August 3- AOTI announced today that has received Health Canada’s Medical Device Approval for its Hyperbox Topical Wound Oxygen (TWO2) therapy systems.
“We are extremely pleased that Health Canada has recognized the value our revolutionary Topical Wound Oxygen (TWO2) system in the treatment of difficult and non healing wounds” stated Mike Griffiths President and CEO of AOTI.
Griffiths added, “ TWO2 therapy not only closes wounds but has been demonstrated to keep problem wounds closed allowing patients to resume a normal active lifestyle while saving significant costs for healthcare system.”
AOTI is founded on a decade of experience in providing innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (two2) therapy is unsurpassed in fully closings Diabetic, Venous and Pressure ulcers alike. AOTI is a private company based in Galway, Ireland with offices throughout the globe. For more information, see www.aotinc.net.